// App-Quantinova.ai

: Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Researchers

Presenter

  • Arthur Bobin

Principal Investigators

  • Aurore Perrot

  • Salomon Manier

  • Lydia Montes

  • Arnaud Jaccard

  • Lionel Karlin

  • Pascal Godmer

  • Denis Caillot

  • Cyrille Hulin

  • Thomas Chalopin

  • Christophe Roul

  • Clara Mariette

  • Sophie Rigaudeau

  • Claire Dingremont

  • Alberto Santagostino

  • Mamoun Dib

  • Margaret Macro

  • Mourad Tiab

  • Kamel Laribi

  • Emmanuelle Bourgeois-Petit

  • Claire Calmettes

  • Frederique Orsini

  • Reza Tabrizi

  • Laure Vincent

  • Mohamad Mohty

  • Cyrille Touzeau

  • Jill Corre

  • Philippe Moreau

  • Thierry Facon

  • Herve Avet Loiseau

  • Xavier Leleu

Medical Centers

  • CH la Roche Sur Yon, La Roche Sur Yon Cedex , France

  • Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France

  • Biostatistics Department, University of Paris, AP-HP, Saint Louis Hospital, Paris, FRA

  • Hôpital Haut Leveque, University Hospital, Pessac, France

  • Clinical Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France

  • Hematology department, Limoges University Hospital, Limoges, France

  • Department of Hematology, Montpellier University Hospital, Montpellier, France

  • Service d'Hématologie, CHU de Grenoble, Grenoble, France

  • Hôpital Haut-Leveque C.H.U. de Bordeaux, Pessac, France

  • Hematology, CH de Troyes, Troyes, France

  • Hematologie - CHU - Hopital du Bocage, Angers, France

  • Bordeaux Hospital University Center (CHU), Lille, France

  • Centre Hospitalier Lyon Sud, Lyon, France

  • Haematology Department, Caen University Hospital, Caen, France

  • Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

  • Hematology department, CHU Amiens, Amiens, France

  • Service Hématologie, CH Annecy, ANNECY, France

  • Centre Hospitalier de Versailles André Mignot, Le Chesnay, France

  • Department of Hematology and Cell therapy, INSERM CIC , Poitiers University Hospital, Poitiers, France

  • Hématologie clinique, CH Le Mans, Le Mans, France

  • La Rochelle Hospital, La Rochelle, FRA

  • Hematology, Hôpital Saint Vincent de Paul, Lille Cedex, FRA

  • EBMT Paris study office / CEREST-TC, Paris, France, Department of Hematology, Saint Antoine Hospital, Paris, France, INSERM UMR , Sorbonne University, Paris, France

  • Institut Universitaire Du Cancer De Toulouse Oncopole, Toulouse, France

  • Department of Hematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France

  • Service de médecine interne, Centre Hospitalier de Tarbes, Tarbes, France

  • Department of Medical Oncology, Hopital Claude Huriez, CHU Lille, Lille, France

  • Department of Haematology, Saint Antoine Hospital, Paris, France

  • Oncologie-Hématologie, Centre Hospitalier de Périgueux, Périgueux, France

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • 5'-nucleotidase

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

  • Isatuximab

  • Sandolase

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Randomized

  • Safety

  • Adaptive

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved